Eli Lilly: The Road To Approval Of Donanemab Is Open


  • Eli Lilly’s stock has seen significant gains due to the success of its GLP-1 franchise and the potential of donanemab for Alzheimer’s disease.
  • The FDA’s Advisory Committee endorsed donanemab for Alzheimer’s treatment, but concerns remain post-approval requirements.
  • Though competition in the Alzheimer’s market is limited, sales projections for anti-amyloid antibodies may be overhyped.
Alzheimer"s disease: the amyloid-beta peptide accumulates to amyloid fibrils that build up dense amyloid plaques.



Eli Lilly (NYSE:LLY) is a big pharma company that is riding on an ever-expanding pipeline of novel applications for its GLP-1 franchise.

The current hot item in Eli Lilly’s pipeline seems to be donanemab, an anti-amyloid antibody for the treatment

Analyst’s Disclosure: I/we have a beneficial long position in the shares of COYA, INMB, SAVA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *